Mountaingate Capital exits Relevate Health after six-year growth bet
What's the deal? Denver-based private equity firm Mountaingate CapitalDealroom has a profile for this one. Try Dealroom → has exited its investment in Relevate Health Group, ending a partnership that began in 2020. Financial terms were not disclosed, and neither party named the buyer.
What each side does: Mountaingate is a lower middle-market firm managing more than $1.2 billion in assets. Relevate is a healthcare commercialisation platform serving pharmaceutical, biotechnology and medical device companies.
What's the endgame? Mountaingate first invested in Relevate to build a larger commercialisation platform for life sciences clients. Over six years, it integrated four add-on acquisitions and backed Relevate's technology, operations and management team.
Under the hood: Relevate's services span medical communications, omnichannel marketing, media, analytics and clinical decision-making programmes. At the centre sits its ELE Decision Engine, which combines analytics, artificial intelligence and first-party healthcare data to guide when and how clients reach professionals and patients.
Houlihan LokeyDealroom has a profile for this one. Try Dealroom → advised Relevate and Mountaingate, and Latham & WatkinsDealroom has a profile for this one. Try Dealroom → served as legal counsel.
What they're saying: "We aligned with Mountaingate around an ambitious shared vision for growth and they steadfastly supported that plan," Relevate co-founder and chairman Jeff SpanbauerDealroom has a profile for this one. Try Dealroom → said. Chief executive officer Tim PantelloDealroom has a profile for this one. Try Dealroom → said the investment helped strengthen the platform and broaden its capabilities.
Bruce Rogers, Mountaingate co-founder and managing director, called it "tremendously rewarding to support the world-class management team at Relevate as they executed the plan we collectively envisioned at the outset of our partnership."
The signal: The exit marks another Mountaingate deal in technology-enabled marketing services, its build-through-acquisition playbook applied to a sector where life sciences firms increasingly want data-driven ways to engage doctors and patients. Relevate said it will keep operating its platform as it enters its next phase.
Read more: citybiz.co
Image credit: nenadstojkovicart
